Rudolph M. Navari's guest appearances

Rudolph M. Navari

Oncology Data Advisor

Adam Carroll

Atopic Dermatitis

Steven Horwitz

Katie Murray

Ian Krop

Lillie Shockney

Gilles Salles

David Penberthy

John Leonard

Carol Viele

Laura Griffith

Louis Diehl

Philip McCarthy

Anjali Advani

Judith Paice

OwlTail

Rudolph M. Navari, MD is the Director of the Cancer Care Program in Central and South America for the World Health Organization. He has practiced oncology for nearly 30 years. His research interests are focused on supportive care in clinical oncology, development of antiemetics, palliative care, and the doctor-patient relationship in clinical oncology. He spoke with Oncology Data Advisor about the progress we’ve made in managing chemotherapy-induced nausea and vomiting (CINV), why patients may underreport their nausea, and considerations when choosing antiemetic regimens. Discussion Notes: On the progress of CINV management over the past 20 years [1:55] On why patients may under report nausea and vomiting [6:31] On misconceptions about CINV among the cancer care team [8:27] On risk factors and potential causes of CINV [11:05] On the effectiveness of dexamethasone-sparing regimens [15:02] On cardiac adverse events of 5HT3-receptor antagonists [17:08] On non-pharmacological treatment options for CINV [19:19] On use of the antipsychotic olanzapine as an antiemetic [21:25] On the remaining challenges in controlling CINV [22:47]

Rudolph M. Navari, MD is the Director of the Cancer Care Program in Central and South America for the World Health Organization. He has practiced oncology for nearly 30 years. His research interests are focused on supportive care in clinical oncology, development of antiemetics, palliative care, and the doctor-patient relationship in clinical oncology. He spoke with Oncology Data Advisor about the progress we’ve made in managing chemotherapy-induced nausea and vomiting (CINV), why patients may underreport their nausea, and considerations when choosing antiemetic regimens. <br><br>Discussion Notes: On the progress of CINV management over the past 20 years [1:55] On why patients may under report nausea and vomiting [6:31] On misconceptions about CINV among the cancer care team [8:27] On risk factors and potential causes of CINV [11:05] On the effectiveness of dexamethasone-sparing regimens [15:02] On cardiac adverse events of 5HT3-receptor antagonists [17:08] On non-pharmacological treatment options for CINV [19:19] On use of the antipsychotic olanzapine as an antiemetic [21:25] On the remaining challenges in controlling CINV [22:47]

Management of Chemotherapy-Induced Nausea and Vomiting With Rudolph M. Navari, MD, PhD, FACP